|
1
|
Harris JR, Lippman ME, Veronesi U and
Willett W: Breast cancer. N Engl J Med. 327:473–480. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Jemal A, Grey N, Ferlay J and
Forman D: Global cancer transitions according to the Human
Development Index (2008–2030): a population-based study. Lancet
Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Buzdar AU: Role of biologic therapy and
chemotherapy in hormone receptor- and HER2-positive breast cancer.
Ann Oncol. 20:993–999. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cohen SM, Mukerji R, Cai S, Damjanov I,
Forrest ML and Cohen MS: Subcutaneous delivery of nanoconjugated
doxorubicin and cisplatin for locally advanced breast cancer
demonstrates improved efficacy and decreased toxicity at lower
doses than standard systemic combination therapy in vivo. Am J
Surg. 202:646–652; discussion 652–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fuertes MA, Castilla J, Alonso C and Pérez
JM: Cisplatin biochemical mechanism of action: from cytotoxicity to
induction of cell death through interconnections between apoptotic
and necrotic pathways. Curr Med Chem. 10:257–266. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leonard BJ, Eccleston E, Jones D, Todd P
and Walpole A: Antileukaemic and nephrotoxic properties of platinum
compounds. Nature. 234:43–45. 1971. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Köberle B, Tomicic MT, Usanova S and Kaina
B: Cisplatin resistance: preclinical findings and clinical
implications. Biochim Biophys Acta. 1806:172–182. 2010.PubMed/NCBI
|
|
8
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
|
|
9
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: a cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu FS: Mechanisms of chemotherapeutic
drug resistance in cancer therapy-a quick review. Taiwan J Obstet
Gynecol. 48:239–244. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Imanshahidi M and Hosseinzadeh H:
Pharmacological and therapeutic effects of Berberis vulgaris and
its active constituent, berberine. Phytother Res. 22:999–1012.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kheir MM, Wang Y, Hua L, Hu J, Li L, Lei F
and Du L: Acute toxicity of berberine and its correlation with the
blood concentration in mice. Food Chem Toxicol. 48:1105–1110. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Satou T, Akao N, Matsuhashi R, Koike K,
Fujita K and Nikaido T: Inhibitory effect of isoquinoline alkaloids
on movement of second-stage larvae of Toxocara canis. Biol Pharm
Bull. 25:1651–1654. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuo CL, Chi CW and Liu TY: The
anti-inflammatory potential of berberine in vitro and in vivo.
Cancer Lett. 203:127–137. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chi L, Peng L, Hu X, Pan N and Zhang Y:
Berberine combined with atorvastatin downregulates LOX-1 expression
through the ET-1 receptor in monocyte/macrophages. Int J Mol Med.
34:283–290. 2014.PubMed/NCBI
|
|
16
|
Zhu Y, Ma N, Li HX, Tian L, Ba YF and Hao
B: Berberine induces apoptosis and DNA damage in MG 63 human
osteosarcoma cells. Mol Med Rep. 10:1734–1738. 2014.PubMed/NCBI
|
|
17
|
Huang ZH, Zheng HF, Wang WL, Wang Y, Zhong
LF, Wu JL and Li QX: Berberine targets epidermal growth factor
receptor signaling to suppress prostate cancer proliferation in
vitro. Mol Med Rep. 11:2125–2128. 2015.
|
|
18
|
Wu K, Yang Q, Mu Y, Zhou L, Liu Y, Zhou Q
and He B: Berberine inhibits the proliferation of colon cancer
cells by inactivating Wnt/β-catenin signaling. Int J oncol.
41:292–298. 2012.PubMed/NCBI
|
|
19
|
Ortiz LM, Lombardi P, Tillhon M and
Scovassi AI: Berberine, an epiphany against cancer. Molecules.
19:12349–12367. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hwang JM, Kuo HC, Tseng TH, Liu JY and Chu
CY: Berberine induces apoptosis through a mitochondria/caspases
pathway in human hepatoma cells. Arch Toxicol. 80:62–73. 2006.
View Article : Google Scholar
|
|
21
|
Lin CC, Yang JS, Chen JT, Fan S, Yu FS,
Yang JL, Lu CC, Kao MC, Huang AC, Lu HF, et al: Berberine induces
apoptosis in human HSC-3 oral cancer cells via simultaneous
activation of the death receptor-mediated and mitochondrial
pathway. Anticancer Res. 27:3371–3378. 2007.PubMed/NCBI
|
|
22
|
Choi MS, Oh JH, Kim SM, Jung HY, Yoo HS,
Lee YM, Moon DC, Han SB and Hong JT: Berberine inhibits
p53-dependent cell growth through induction of apoptosis of
prostate cancer cells. Int J Oncol. 34:1221–1230. 2009.PubMed/NCBI
|
|
23
|
Kim S, Han J, Kim NY, Lee SK, Cho DH, Choi
MY, Kim JS, Kim JH, Choe JH, Nam SJ, et al: Effect of berberine on
p53 expression by TPA in breast cancer cells. Oncol Rep.
27:210–215. 2012.
|
|
24
|
Kim JB, Yu JH, Ko E, Lee KW, Song AK, Park
SY, Shin I, Han W and Noh DY: The alkaloid Berberine inhibits the
growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell
lines by inducing cell cycle arrest. Phytomedicine. 17:436–440.
2010. View Article : Google Scholar
|
|
25
|
Katiyar SK, Meeran SM, Katiyar N and
Akhtar S: p53 cooperates berberine-induced growth inhibition and
apoptosis of non-small cell human lung cancer cells in vitro and
tumor xenograft growth in vivo. Mol Carcinog. 48:24–37. 2009.
View Article : Google Scholar
|
|
26
|
Tan W, Li Y, Chen M and Wang Y: Berberine
hydrochloride: anticancer activity and nanoparticulate delivery
system. Int J Nanomedicine. 6:1773–1777. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kang JX, Liu J, Wang J, He C and Li FP:
The extract of Huanglian, a medicinal herb, induces cell growth
arrest and apoptosis by upregulation of interferon-beta and
TNF-alpha in human breast cancer cells. Carcinogenesis.
26:1934–1939. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu J, He C, Zhou K, Wang J and Kang JX:
Coptis extracts enhance the anticancer effect of estrogen receptor
antagonists on human breast cancer cells. Biochem Biophys Res
Commun. 378:174–178. 2009. View Article : Google Scholar
|
|
29
|
Tsang CM, Lau EP, Di K, Cheung PY, Hau PM,
Ching YP, Wong YC, Cheung AL, Wan TS, Tong Y, et al: Berberine
inhibits Rho GTPases and cell migration at low doses but induces G2
arrest and apoptosis at high doses in human cancer cells. Int J Mol
Med. 24:131–138. 2009.PubMed/NCBI
|
|
30
|
Singh T, Vaid M, Katiyar N, Sharma S and
Katiyar SK: Berberine, an isoquinoline alkaloid, inhibits melanoma
cancer cell migration by reducing the expressions of
cyclooxygenase-2, prostaglandin E2 and prostaglandin
E2 receptors. Carcinogenesis. 32:86–92. 2011. View Article : Google Scholar
|
|
31
|
Krey AK and Hahn FE: Berberine: Complex
with DNA. Science. 166:755–757. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peng PL, Kuo WH, Tseng HC and Chou FP:
Synergistic tumor-killing effect of radiation and berberine
combined treatment in lung cancer: the contribution of autophagic
cell death. Int J Radiat Oncol Biol Phys. 70:529–542. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu Q, Jiang H, Liu Z, Wang Y, Zhao M, Hao
C, Feng S, Guo H, Xu B, Yang Q, et al: Berberine radiosensitizes
human esophageal cancer cells by downregulating homologous
recombination repair protein RAD51. PLoS One. 6:e234272011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tong N, Zhang J, Chen Y, Li Z, Luo Y, Zuo
H and Zhao X: Berberine sensitizes mutliple human cancer cells to
the anticancer effects of doxorubicin in vitro. Oncol Lett.
3:1263–1267. 2012.PubMed/NCBI
|
|
35
|
Guo N, Yan A, Gao X, Chen Y, He X, Hu Z,
Mi M, Tang X and Gou X: Berberine sensitizes rapamycin mediated
human hepatoma cell death in vitro. Mol Med Rep. 10:3132–3138.
2014.PubMed/NCBI
|
|
36
|
Zhu Q, Chang Y, Yang J and Wei Q:
Post-translational modifications of proliferating cell nuclear
antigen: a key signal integrator for DNA damage response (Review).
Oncol Lett. 7:1363–1369. 2014.PubMed/NCBI
|
